Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Overview

This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme

Description

The patients with primary glioblastoma multiforme (GBM) have high mortality and morbidity. Even with best conventional therapy (surgery, radiation, and chemotherapy), the most of median survivals are less than 2 years. The one-year progression-free survival (PFS) is less than 20%. Recently, the immune therapy is a new promising therapy for GBM from the evidences of published experimental data and clinical trials.

However, the outcomes of immune therapy are still equivocal. The critical point of immune therapy is strongly influenced by tumor microenvironment. Up to now, for example, immune checkpoint inhibitor such as programmed cell death protein ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) was found to induce exhaustion of CD8 T cell by of PD-1/PD-L1 reaction. Unfortunately, GBM cells always have high PD-L1 expression. It means the higher PD-1 level of T-cell indicates the higher immune suppression by GBM tumor cells.

In the investigators preclinical study, the best murine survival was found to be the combination outcome of dendritic cell (DC) with anti-PD-1 therapy which was better than that of DC therapy only. From previously ADCV-treated patients, the median of PD-1/CD8 was 0.21. When the PD-1/CD8 ratio less than 0.21, this patient is defined as with low PD-1 level.

From the investigators previous experience, patients with low PD-1/CD8 ratio had far better 2-year overall survival (OS) than patients with high PD-1/CD8 ratio in ADCV treatment. On the other hand, it showed that OS and PFS had significant reverse correlation with PD-1 level of Tcell during DC immunotherapy. Considering the needs and benefit of patients, the new autologous dendritic cell vaccine (ADCV01) is proposed to be added on conventional therapy in low PD-1 expressed GBM patients and evaluate its safety and efficacy.

In this study, only newly diagnosed primary GBM (wild-type Isocitrate Dehydrogenase 1, IDH-1) patients will be enrolled in this clinical trial. In addition to fulfilling all inclusion criteria without matching any of the exclusion criteria, patients will undergo tumor resection and less than 25% of residual tumor size, followed by being subjected to histological analysis. Examinations of molecular diagnostics including IDH-1 for confirmation of IDH-1 wild-type GBM according to the 2016 WHO Classification of Tumors of the Central Nervous System, and cut-off criteria for expression levels of PD-1 and CD8 (PD-1/CD8 ratio less than 0.21) will be screened for the eligibility to participate in this study and MGMT status will also be determined.

After tumor resection, all eligible patients will receive standard radiotherapy (RT) plus Temozolomide (Temodal, TMZ), followed by adjuvant treatment of TMZ. Patients assigned to the investigational group will receive ADCV01 administration as an add-on treatment after operation in this study.

This study aims to treat eligible patients with ADCV01 as an add-on immunotherapy along with post-surgery GBM treatment and compare the treatment to the conventional therapy (RT plus standard TMZ chemotherapy) alone on the basis of PFS in an unbalanced allocation (investigational group : control group = 2:1). After tumor resection, patients assigned to the control group will receive RT plus TMZ, followed by the scheduled evaluation visits. For patients assigned to the investigational drug group, a standard of 10 doses of ADCV01 (2±0.5 × 10^7 cell/dose) in addition to conventional therapy will be administered.

The assessment of tumor response is based on [Update Response Assessment Criteria for High-Grade Gliomas, Response Assessment in Neuro-Oncology (RANO)] assessed by the on-site investigator and Blinded Independent Central Review (BICR) independently. If needed, the repeat operation for decompressive craniotomy evaluated by the on-site neurosurgeon for relief of increased intracerebral pressure (IICP), or for lifesaving will be allowed in both groups. However, in this study, the reoperation for recurrent tumor will be allowed.

RT will be given if feasible considering the total RT accumulatively given is not enough when tumor recurs (total dose 60 Gy). Gamma knife will not be used for recurrent tumor in this study which is different application from previous research.

Regardless of receiving re-operation or not in both groups, TMZ treatment will be shifted to anti-angiogenic therapy (AVASTIN®) 10 mg/kg/2weeks for 6 doses after patients have recurrence of GBM. Pseudo-progression may lead to either premature termination of therapy or unnecessary debulking surgeries. Therefore, adjuvant TMZ is recommended to be continued for a minimum of 3 cycles (along with ADCV01 treatment in the first 3 months of the adjuvant TMZ period), after which other imaging techniques (e.g., Gdenhancing MRI and proton magnetic resonance spectroscopy) should be used to ascertain progression. TMZ is not continuously used whenever recurrence. On this end, the treatment course is complete.

If the recurrent GBM in patients assigned to the investigational group is occurred before completing 10 doses of ADCV01 treatments, the patient will be treated by the remaining ADCV01 and complete the originally scheduled treatment.

In this phase II study, 24 eligible primary GBM patients who are with low PD-1/CD8 ratio will be recruited. There will be 16 patients with combination of ADCV01 and conventional therapy, and 8 patients with conventional therapy only. In this trial, the treatment efficacy of ADCV01 measured by one-year PFS rate will be evaluated at the end of phase II study. Because PFS was surrogate endpoint of overall survival in GBM by literature-based meta-analysis from 91 clinical trials, the 1-year PFS rate will be the primary endpoint of GBM clinical trial.

This study is designed with open-label and randomized parallel group. To date, 34 clinical trials of DC for GBM published up to 2017 in ClinicalTrials.gov, there are 5/34 trials designed by double blinded method and 2/34 trials by single blinded and most of 27/34 trials by open-label (please see ref. ClinicalTrials.gov). The other reason for open-label is that the apheresis for control patients is an invasive procedure. GBM is a not easily curable disease; patients with MGMT methylation have a better survival than with unmethylation. In this trial, MGMT status will be evaluated in all tumor specimens for further subgroup analysis.

Eligibility

Inclusion Criteria:

Stage I (Pre-screening)

1. Patients are ≥ 20 and ≤ 75 years of age at brain tumor resection surgery.
2. Patients with newly diagnosed single, primary, WHO grade IV, glioblastoma (except for locating on brainstem or cerebellum) scheduled to undergo craniotomy tumor excision, and are willing to preserve the resected tumor cells enabling the production of ADCV01.
3. Patients undergo tumor resection by aid of neuro-navigation without receiving any intracranial implantation therapies (e.g., BCNU wafer).
4. Only one GBM tumor number.
5. Patients must be able to understand and sign the informed consent documents and aware of the investigational nature of the study.
6. Patients have the expected life expectancy of > 12 weeks at the pre-screening visit as judged by the investigator.
7. Patients with stable vital sign and KPS ≥ 70 at the pre-screening visit.
8. Patients with adequate renal function at the pre-screening visit:

   serum creatinine < 1.8 mg/dL; creatinine clearance > 30 mL/min

9. Patients with adequate liver function at the pre-screening visit:

   AST, ALT, and ALP ≤ 3× upper limit of normal (ULN); and total bilirubin < 3 mg/dL

10. Patients with prothrombin time and activated partial thromboplastin time ≤ 1.5× ULN at the pre-screening visit
11. Patients with adequate hematopoietic function at the prescreening and before administration of study medication
    1. Absolute neutrophil count (ANC) ≥ 1,000 cells/μL
    2. Platelets ≥ 100,000 counts/μL
    3. Total white blood cell (WBC) ≥ 2,000 cells/μL
    4. Hemoglobin ≥ 8 g/dL
12. All male and female patients with child-bearing potential (between puberty and 2 years

    after menopause) must be practicing sexual abstinence and be willing to continue to use a medically acceptable form of birth control for at least 1 month prior to screening (that period will extend to 3 months for oral contraceptive use). The patients should use appropriate contraceptive method(s) as shown below, until at least 6 months after the last dose of ADCV01 administration.

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, thermal symptom post-ovulation methods) and withdrawal are not acceptable methods of ontraception).
    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before administration of study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    3. Male sterilization (at least 6 months prior to screening). For female subjects in the study, the vasectomized male partner should be the sole partner for that subject
    4. Combination of any two of the following listed methods:

             (d.1+d.2 or d.1+d.3, or d.2+d.3): d.1 Use of oral, injected, or implanted hormonal
             methods of contraception or other forms of hormonal contraception that have comparable
             efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone
             contraception. d.2 Placement of an intrauterine device (IUD) or intrauterine system
             (IUS). d.3 Barrier methods of contraception: Condom or Occlusive cap (diaphragm or
             cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.
         13. Patients agree to be in compliance with treatment plan as planned in the clinical
             protocol.
             Stage II (Screening/Randomization) In addition to fulfill the criteria in Stage I,
             following criteria should be met to be eligible for remaining in the study.
         14. Patients' resected brain tumors are pathologically confirmed cases of the IDH-1
             wild-type glioblastoma, and patients are willing to do monocyte-collecting apheresis
             at the screening/randomization visit.
         15. At the screening/randomization visit, patients' resected brain tumors are confirmed of
             low PD-1+/ CD8+ ratio (ratio <0.21).
         16. Residual tumor with less than 25% contrast-enhancing mass on post-surgical brain MRI
             (within 2 days post-operation) as assessed by the neurosurgeon and/or radiologist.
        Exclusion Criteria:
        Stage I (Pre-screening)
          1. Number of GBM is more than one
          2. Patient who has participated in other investigational studies within 4 weeks prior to
             pre-screening
          3. Patient with known or suspected hypersensitivity to ADCV01 or its excipients
          4. Patient who has a history of hypersensitivity reaction (e.g., urticarial, allergic
             reaction including anaphylaxis, toxic epidermal necrosis, and Stevens-Johnson
             syndrome) to dacarbazine (DTIC) or any components of medications of temozolomide and
             bevacizumab
          5. Patient has acute infectious disease or acute cardiovascular disease; clinically
             manifest myocardial insufficiency or history of myocardial infarction during the past
             6 months prior to prescreening; or has active uncontrolled arterial hypertension as
             supported by medical history.
          6. Patient has clinically significant immuno-compromised condition (other than that
             related to the use of corticosteroids), is human immunodeficiency virus positive
             (anti-HIV and nucleic acid test) or medical condition requiring systemic
             immunesuppressive treatments.
          7. Patient with active rheumatic disease or other collagen vascular disease, or is with
             active autoimmune disorder or known history of an autoimmune neurologic condition
             (e.g., Guillain-Barre syndrome). Patients with vitiligo, type 1 diabetes mellitus,
             hypothyroidism due to autoimmune condition, only requiring hormone replacement therapy
             are permitted to enroll.
          8. Patients with psoriasis requiring systemic therapy, or conditions expected to recur in
             the presence of an external trigger
          9. Patient with syphilis, acute HBV, HCV (except hepatitis carriers), HTLV-I/II, CMV, or
             an increased risk (or has been diagnosed) for human transmissible spongiform
             encephalopathy (TSE); including Creutzfeldt-Jakob disease (CJD)
         10. Patient with history of coagulation disorder associated with bleeding or recurrent
             thrombotic events
         11. Patient with medical, social, or psychological factors interfering with compliance of
             the study
         12. Female patient who is lactating, pregnant, or planned to be pregnant
         13. Inability to undergo MRI for any reason
         14. History of malignancy other than glioma that is not stable in the past 5 years prior
             to pre-screening (informed consent form signing date)
         15. Patient not suitable to participate the trial as judged by the investigator. Stage II
             (Screening/Randomization)
             The patient will be no longer eligible to participate the study if he/she met any of
             the following criteria:
         16. GBM patients with high PD-1+/CD8+ ratio ≥ 0.21
         17. GBM patients with mutant IDH-1
         18. Residual tumor volume more than 25% of pre-operative tumor size.